# Sermorelin FAQ: GHRH(1-29) Questions Answered From the Research > Sermorelin FAQ: does it work, how it raises IGF-1, sleep and fat questions, vs ipamorelin and CJC-1295, and safety — each answer drawn from the cited literature on Sermorelin. Direct answers drawn from the published literature — efficacy, IGF-1, sleep, fat, the analog comparisons, and the honest limits of the adult data. ## Does sermorelin work? In healthy older men, GHRH(1-29) at 0.5-1 mg twice daily for 14 days produced dose-related increases in 24-hour GH and IGF-1, with high-dose values no longer differing from young men [5]. In GH-deficient children, once-daily subcutaneous GHRH(1-29) accelerated first-year height velocity from about 4.1 to 7-8 cm/year [2]. These are studied outcomes, not a treatment recommendation. ## How long does it take for sermorelin to work? Pharmacokinetic studies show GH rises within an hour of a single dose and stays elevated for roughly 3 hours despite the peptide's ~10-12 minute plasma half-life [3]. Changes in IGF-1 and body composition in adult research accrued over weeks of repeated dosing [5]. Reported in studies, not a personal timeline. ## Will sermorelin raise my IGF-1 levels? In healthy older men, 14 days of subcutaneous GHRH(1-29) produced dose-related rises in IGF-1, and at the high dose IGF-1 no longer differed from that of young men, with no change in fasting glucose [5]. IGF-1 is produced mainly by the liver in response to GH, so the rise follows GH stimulation. ## Is 3 months of sermorelin enough? Study durations vary widely. The adult GH-axis study in older men ran 14 days and still showed reversal of age-related GH/IGF-1 declines [5]; the pediatric efficacy trial measured first-year growth over 12 months [2]. There is no established adult anti-aging duration — long-term adult data remain limited [9]. ## Is long-term sermorelin use safe? Long-term tolerability data specifically for adult use are limited, and an Annals of Internal Medicine editorial cautioned that growth-hormone-secretagogue use to prevent or treat aging is "not yet ready for prime time" [9]. Because GH and IGF-1 are mitogenic, chronically raising them is a recognized theoretical safety consideration [6]. This is research context, not safety guidance. ## What is sermorelin? Sermorelin is the amidated synthetic 29-amino-acid fragment (GHRH(1-29)NH2 / GRF(1-29)) corresponding to the active amino-terminal portion of growth-hormone-releasing hormone — the shortest fragment retaining full activity at the GHRH receptor [1]. It is a pituitary growth-hormone secretagogue; it was formerly FDA-approved as a pediatric GH-deficiency drug (withdrawn from the US market in 2008 for commercial reasons) and is now prepared by compounding pharmacies. ## What does sermorelin do to the body? It binds GHRH receptors on anterior-pituitary somatotrophs, activating the adenylate-cyclase / cAMP / PKA pathway to stimulate synthesis and pulsatile release of the body's own growth hormone, which in turn raises hepatic IGF-1 [1]. Because it acts upstream, somatostatin and IGF-1 negative feedback stay intact, preserving the natural pulsatile GH pattern [4][6]. ## How does sermorelin compare to CJC-1295? Sermorelin is native GHRH(1-29) with a short ~10-12 minute plasma half-life [3]. That brevity motivated longer-acting analogs: a D-Ala2 substitution and the Drug Affinity Complex (DAC) technology behind CJC-1295, where a maleimide group binds serum albumin to extend the half-life. Both engage the same GHRH receptor; the difference is duration of action. ## Sermorelin vs ipamorelin: what is the difference? They act through different receptors. Sermorelin is a GHRH analog acting on the pituitary GHRH receptor; ipamorelin is a growth-hormone-releasing peptide (GHRP) acting on the ghrelin / GH-secretagogue receptor [6]. Mechanistically, combining a GHRH analog with a GHRP amplifies GH pulse amplitude versus either class alone. ## What is sermorelin used for? Its historical FDA-approved use was to accelerate growth in children with growth-hormone deficiency / short stature [2]. Subsequent research has studied GHRH(1-29) and its analogs in adult GH-axis aging, body composition, cognition, and sleep. It is studied as a research peptide; these pages describe findings, not human treatment. ## Does sermorelin actually help with sleep, or is it waking me up instead? Sleep onset and slow-wave sleep coincide with the nocturnal GH release that bedtime GHRH dosing leverages [13], and blocking GHRH receptors suppresses nocturnal GH without abolishing slow-wave sleep [14]. GHRH's efficacy in modulating sleep-endocrine activity is reduced in the elderly [15]. These are physiology findings, not a claim about individual sleep experience. ## Why is it recommended to inject sermorelin at night? GH is secreted in pulses, especially during slow-wave sleep, and slow-wave sleep coincides with the dominant nocturnal GH pulse [13]. Research protocols therefore administered GHRH(1-29) at bedtime to align with that endogenous pulse — the pediatric efficacy trial used once-daily subcutaneous bedtime dosing [2]. Described as a study protocol, not a dosing instruction. ## Does sermorelin burn fat? The GH/IGF-1 axis has a known role in body composition, and in the cognition RCT the stabilized GHRH analog tesamorelin reduced percent body fat by 7.4% over 20 weeks [10]. Reviews discuss GH/IGF-1-axis modulation among strategies for age-related change [11]. Anti-aging and body-composition marketing outpaces the evidence; these are studied outcomes, not proven benefits. ## Does sermorelin build muscle? A review frames GH/IGF-1-axis modulation, including GHRH secretagogues, among candidate strategies to counteract sarcopenia (age-related muscle loss) in older adults [11]. Sermorelin raises GH and IGF-1, which mediate anabolic signaling, but rigorous adult muscle-outcome data are limited and benefit is not established. Research context only. ## How does sermorelin differ from direct HGH injections? Sermorelin acts upstream on the pituitary to stimulate the body's own pulsatile GH, leaving somatostatin and IGF-1 feedback intact, whereas exogenous HGH supplies the hormone directly and bypasses that feedback. An editorial argues sermorelin may be a more physiologic approach to adult-onset GH insufficiency than recombinant GH [4]. ## Does sermorelin affect testosterone? The research literature characterizes sermorelin as acting on the GH/IGF-1 somatotropic axis, distinct from the gonadal (testosterone) axis. The studies summarized here report GH and IGF-1 outcomes, not testosterone changes, so any testosterone link is not established in this evidence set. Described as research scope, not a recommendation. ## Can sermorelin or GHRH improve cognition in older adults? In a randomized, double-blind, placebo-controlled trial of 152 older adults (66 with mild cognitive impairment), 20 weeks of a daily GHRH analog (tesamorelin, 1 mg before bedtime) had a favorable effect on cognition (P=0.03), raised IGF-1 by 117% within the physiologic range, and cut body fat 7.4% (the SMART trial, NCT00257712) [10]. In aged rodents, chronic [D-Ala2]-GHRH attenuated age-related spatial-memory deficits [12]. ## What are the side effects of sermorelin? Long-term tolerability data specifically for adult use remain limited [6]. Because GH and IGF-1 are mitogenic, chronically raising them is a recognized theoretical oncologic consideration for any GH-axis intervention, even though sermorelin works through the body's own feedback-regulated secretion. Authorities have cautioned that secretagogue use for aging is not established [9]. Research context, not a safety profile for use. ## When is the best time to take sermorelin? Research protocols specified bedtime administration to coincide with the dominant nocturnal GH pulse during slow-wave sleep [13][2]. Aligning dosing with that endogenous pulse is the rationale reported in the literature. Stated as a study-protocol observation, not a personal dosing instruction. ## Sermorelin before and after: what changes do studies report? Controlled studies report objective biomarker and growth changes rather than anecdotal transformations: dose-related rises in 24-hour GH and IGF-1 in older men, with high-dose values matching young men [5]; first-year height velocity rising from about 4.1 to 7-8 cm/year in GH-deficient children [2]; and, for the analog tesamorelin, IGF-1 +117% and body fat -7.4% over 20 weeks [10]. --- The sermorelin literature read along one calm horizon — each GH and IGF-1 figure carried back to its study, the formerly-approved-now-compounded history stated straight, and the open water where the adult anti-aging data stop left plainly unfilled; no clinic behind the tide and nothing here dispensed, dosed, or sold.